Search

Displaying results 6641 - 6650 of 10000 in total
  1. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88]

  2. Drug

    Anisodamine

    go.drugbank.com/drugs/DB11785
    Investigational

    Anisodamine has been investigated for the treatment of Intestinal Diseases.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  4. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. … CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain.

  5. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  6. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. … Haloprogin is no longer available in the United States and has been discontinued.

  7. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

  8. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  9. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

    Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
  10. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose